RecruitingNot Applicable

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

United Kingdom800 participantsStarted 2021-11-19

Plain-language summary

This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Identify a difference in expression profiles, using proteomics, genomics, epigenomics, in tissue samples obtained pre- and post-NCT and post-surgery alone

Timeframe: Through study completion, average 4 years

Develop an understanding of radiomic profiles for patients treated with NCT.

Timeframe: Through study completion, average 4 years

Develop an electronic STS Tissue Atlas for 5 high risk subtypes.

Timeframe: Through study completion, average 4 years

Develop and characterize patient derived models to investigate biology of high-risk sarcomas and directly test predicted therapeutic interventions

Timeframe: Through study completion, average 4 years

Develop a nomogram app to predict benefit of NCT and predict risk of recurrence.

Timeframe: Through study completion, average 4 years

Trial details

NCT IDNCT07432932

SponsorRoyal Marsden NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-31

Contact for this trial

Stephanie Elston, MSc

02073528171 PANTHRS.Trial@rmh.nhs.uk

View on ClinicalTrials.gov More Sarcoma trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.

What they're measuring

Identify a difference in expression profiles, using proteomics, genomics, epigenomics, in tissue samples obtained pre- and post-NCT and post-surgery alone

Timeframe: Through study completion, average 4 years

Develop an understanding of radiomic profiles for patients treated with NCT.

Timeframe: Through study completion, average 4 years

Develop an electronic STS Tissue Atlas for 5 high risk subtypes.

Timeframe: Through study completion, average 4 years

Develop and characterize patient derived models to investigate biology of high-risk sarcomas and directly test predicted therapeutic interventions

Timeframe: Through study completion, average 4 years

Develop a nomogram app to predict benefit of NCT and predict risk of recurrence.

Timeframe: Through study completion, average 4 years